Clinical trials for Breast cancer

200 currently recruiting clinical trials

Phase 3 Breast cancer #NCT06382948
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
ESR
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
8 recruiting sites
MedSIR
Phase 3 Breast cancer #NCT06790693 #2024-516162-11-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
12 recruiting sites
Hoffmann-La Roche
Phase 3 Breast cancer #NCT06790693 #2024-516162-11-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
12 recruiting sites
Hoffmann-La Roche
Phase 3 Breast cancer #NCT06492616 #2024-515445-42-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Excluded previous treatments at localized stage
Hormone therapy
21 recruiting sites
Stemline Therapeutics, Inc.
Phase 3 Breast cancer #NCT06435429
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Jazz Pharmaceuticals
Phase 3 Breast cancer #NCT06103864 #2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT06103864 #2023-503675-24-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Required PDL1 statuses
PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%)
8 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT06982521 #2025-523083-21-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
None 1 2
Required previous treatments at localized stage
Targeted therapy
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy Hormone therapy
Excluded genetic anomalies
AKT PTEN
Excluded previous treatments at localized stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
16 recruiting sites
Relay Therapeutics, Inc.
Phase 3 Breast cancer #NCT06380751
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
BRCA 1/2 PALB2
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
AstraZeneca
Phase 3 Breast cancer #NCT05952557 #2023-504031-41-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Chemotherapy Radiotherapy Hormone therapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
21 recruiting sites
AstraZeneca